Cardiovascular Therapy: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Editorial   
  • Cardiovasc Ther 2016, Vol 1(1): e101

An Example of Controversies on Anti-fibrosis Therapies in Cardiovascular Diseases: Transforming Growth Factor β1

Masao Kakoki*
Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, USA
*Corresponding Author : Masao Kakoki, Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, USA, Tel: 919 966 6915, Email: mkakoki@med.unc.edu

Received Date: Dec 14, 2015 / Accepted Date: Dec 14, 2015 / Published Date: Dec 29, 2015

Keywords: Transforming growth factor; hypomorphic mutations

Citation: Kakoki M (2015) An Example of Controversies on Anti-fibrosis Therapies in Cardiovascular Diseases: Transforming Growth Factor β1. Cardiovasc Ther 1: e101.

Copyright: © 2015 Kakoki M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top